Table 1.
Baseline patient demographics and disease characteristics
| Characteristics | Patients (N=36) |
|---|---|
| Age, years | 62 (28-75) |
| Sex | |
| Male | 23 (63.9) |
| Female | 13 (36.1) |
| ECOG performance status | |
| 0 | 28 (77.8) |
| 1 | 8 (22.2) |
| Type of tumor | |
| Primary | 24 (66.7) |
| Recurrent | 12 (33.3) |
| Size of primary tumor, cm | |
| ≤5 | 14 (38.9) |
| >5 | 22 (61.1) |
| Lymph node status | |
| Negative | 14 (38.9) |
| Positive | 22 (61.1) |
| TNM stage | |
| II | 3 (8.3) |
| III | 33 (91.7) |
| CEA, ng/mL | 4 (1-25) |
| CA19-9, ng/mL | 1243 (2->12,000) |
| TMB status | |
| High | 15 (41.7) |
| Low | 21 (58.3) |
| PD-L1 result | |
| Negative | 30 (83.3) |
| Positive | 6 (16.7) |
| Microsatellite status | |
| MSI | 4 (11.1) |
| MSS | 32 (88.9) |
| Multifocal lesions | |
| Single | 20 (55.6) |
| Multiple | 16 (44.4) |
| Albumin, g/L | 36 (28-49) |
| TBIL, μmol/L | 14.3 (3.5-33.0) |
| Cirrhosis | |
| Yes | 11 (30.6) |
| No | 25 (69.4) |
Data are median (range) or n (%)
CA carbohydrate antigen, CEA carcinoembryonic antigen, ECOG Eastern Cooperative Oncology Group, MSI microsatellite instability, MSS microsatellite stability, PD-L1 programmed death-ligand 1, TBIL total bilirubin, TMB tumor mutational burden, TNM tumor-node-metastasis